Antibodies specific for CLL-1

1. A method of treating a myeloproliferative disorder in an individual, wherein the myeloproliferative disorder is selected from the group consisting of: acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), and myelodisplastic syndrome (MDS), comprising administering to the individual a pharmaceutical composition comprising an antibody, wherein the antibody is conjugated to a cytotoxic/therapeutic compound or has the ability to induce antibody dependent cell-mediated cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activity and wherein the antibody is selected from the group consisting of:

an antibody comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NOs:51, 59, and 67, and light chain CDRs of SEQ ID NOs:75, 83, and 91;

an antibody comprising heavy chain CDRs of SEQ ID NOs:52, 60, and 68, and light chain CDRs of SEQ ID NOs:76, 84, and 92; and

an antibody comprising heavy chain CDRs of SEQ ID NOs:53, 61, and 69 and light chain CDRs of SEQ ID NOs:77, 85, and 93,

thereby treating the myeloproliferative disorder in the individual.

2. The method of claim 1 , wherein the antibody is conjugated to a cytotoxic/therapeutic compound.

3. The method of claim 1 , wherein the individual has been diagnosed with a myeloproliferative disorder or has undergone therapy for a myeloproliferative disorder.

4. The method of claim 1 , wherein the antibody is humanized.

5. The method of claim 1 , wherein the antibody is an Fv antibody fragment.

6. The method of claim 1 , wherein the antibody has the ability to induce ADCC or CDC activity.

7. The method of claim 1 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 6.

8. The method of claim 1 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 10.

9. The method of claim 1 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.

10. The method of claim 2 , wherein the cytotoxic/therapeutic agent is selected from saporin, doxorubicin, daunomycin, a vinca-alkaloid, a taxoid, Maytansin, auristatin, calicheamicin, duocarmycin, and a pyrrolobenzodiazepine dimer.

11. The method of claim 2 , wherein the antibody is humanized.